Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.58 |
| ▸ | RECQL | P46063 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | USP2 | O75604 | 6/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 10/20 | 0.54 |
| ▸ | BLM | P54132 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | S100A4 | P26447 | 6/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 5/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rodorubicin SCHEMBL29352818 | 1.00 | MEN1 (0.58) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL30504362 | 0.97 | PTGS1 (0.56) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL29403905 | 0.95 | PTGS1 (0.54) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL29356967 | 0.92 | PTGS1 (0.57) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL29557045 | 0.92 | MMP2 (0.58) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL29884381 | 0.92 | PTGS1 (0.67) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL29381144 | 0.88 | PTGS1 (0.50) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL22589699 | 0.87 | MEN1 (0.72) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL2136732 | 0.87 | MEN1 (0.72) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL30714406 | 0.87 | MEN1 (0.72) | MEN1KMT2ARECQLMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22656 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4698185-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | Osasuna Therapeutics SA (CH) | 2026-02-25 | — | — | EP | claimed |
| EP-4694935-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| CN-1616099-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-05-18 | — | — | CN | claimed |
| EP-1286692-A4 | INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS | IDEC PHARMA CORP (US) | 2004-11-17 | — | — | EP | claimed |
| WO-2004050057-A2 | AN EXOPOLYSACCHARIDES DELIVERY SYSTEM FOR ACTIVE MOLECULES | TECHNOLOGIES BIOLACTIS INC. (CA) | 2004-06-17 | — | — | WO | claimed |
| CN-1437478-A | Intrathecal administration of rituximab for the treatment of central nervous system lymphomas | IDEC PHARMA CORP (US) | 2003-08-20 | — | — | CN | claimed |
| EP-1286692-A1 | INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS | Idec Pharmaceuticals Corporation (US) | 2003-03-05 | — | — | EP | claimed |
| US-20020009444-A1 | Intrathecal administration of rituximab for treatment of central nervous system lymphomas | IDEC PHARMACEUTICALS CORPORATION (US) | 2002-01-24 | — | — | US | claimed |
| WO-2001080884-A1 | INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS | IDEC PHARMACEUTICALS CORPORATION (US) | 2001-11-01 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0325113-A1 | Stabilised dried preparation containing cytostatic anthracyclin antibiotics, and processes for preparing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-07-26 | — | — | EP | claimed |